To eliminate the problems associated with the use of extraneous adjuvants we have designed a SelfAssembling Protein Nanoparticle (SAPN) containing epitopes from the Plasmodium falciparum circumsporozoite protein (PfCSP) (designated FMP014) and portions of the TLR5 agonist flagellin (designated FMP014 D0D1 ) as an intrinsic adjuvant. By combining different molar ratios of FMP014 to FMP014 D0D1 monomers before self-assembly, we generated multiple nanoparticles and investigated their biophysical characteristics, immunogenicity and protective efficacy. Immunization with the construct formulated with the ratio 58:2 of FMP014 to FMP014 D0D1 had the highest protective efficacy against a challenge with a transgenic P. berghei sporozoite expressing PfCSP. Increasing the proportion of flagellin per particle resulted in an inverse relationship with levels of both antibody titers and protection. The cytokine profiles of the various immunization groups were evaluated and quantitative amounts of the cytokines IL-2, IFN-c, IL-12/p70 (Th1); IL4, IL5 (Th2); TNF-a, IL1b, IL-6, KC/GRO (pro-inflammatory), and IL-10 (immunomodulatory) were measured. The relationship of the cytokines to each other revealed a strong immunomodulatory effect depending on the proportion of flagellin in the construct. Our results demonstrate that SAPNs with flagellin may be a promising strategy for the development and delivery of a safe vaccine for infectious diseases.
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Introduction
The formulation science and fiscal costs associated with vaccine development are significant. Typically, recombinant protein vaccines require an adjuvant to be sufficiently immunogenic to induce a response that mediates sterile protection. The formulation with adjuvants often requires detailed mixing processes that, due to the nature of the adjuvants, cannot generally be applied to all proteins. Designing a self-adjuvanted vaccine addresses the issue of access to adjuvants, formulation and manufacturing costs.
Self-Assembling Protein Nanoparticles (SAPNs) form when monomer proteins oligomerize into particles that function as a particulate repetitive antigen display. We recently reported a SAPN monomer design that included bacterial flagellin and avian or human flu epitope sequences [1] . The nanoparticles formed from these monomers were able to confer complete protection from a lethal challenge of human flu in a mouse model. The protection was dependent on the dose and concentration of flagellin contained in the SAPNs.
Flagellin is a pathogen associated molecular pattern (PAMP) present on flagellated bacteria that stimulates Toll-Like Receptor 5 (TLR5) on immune cells [2] . Numerous studies have indicated that flagellin functions as a strong immune-potentiator, recruiting and activating innate and adaptive immune cells, increasing antigen processing, and has the potential to induce both humoral and cellular immune responses as well as immunological memory [2] [3] [4] [5] [6] [7] .
The SAPN malaria vaccine FMP014 [8] is self-assembled from monomer proteins containing two regions of the P. Abbreviations: CS, circumsporozoite; CSP, circumsporozoite protein; Pf, Plasmodium falciparum; Pb, Plasmodium berghei; SAPN, self-assembling protein nanoparticles; FMP014, WRAIR's P. falciparum malaria protein vaccine candidate number fourteen; SA-FMP014, Self-Adjuvanted FMP014.
(Pf) circumsporozoite protein (PfCSP), the carboxy-terminal region called aTSR and six copies of the NANP repeat peptide ((NANP) 6 ) found in the PfCSP central domain. To create a flagellin containing monomer, FMP014 D0D1 , the (NANP) 6 region in the FMP014 monomer was replaced with the amino acid sequence for the D0 and D1 domains of bacterial flagellin leaving the FMP014 core oligomerization domains and the aTSR region intact. To make particles that contained different amounts of the flagellin domains the FMP014 D0D1 monomers were mixed, in different ratios, with the FMP014 monomers to generate flagellin-based self-adjuvanted FMP014 (SA-FMP014) SAPN.
In the present study, we describe the design, expression, biophysical characterization, immunogenicity and protective efficacy data of different SA-FMP014. We identified the construct with an optimal FMP014 and FMP014 D0D1 ratio based on immunogenicity and protection against a transgenic P. berghei sporozoite challenge. The data demonstrate that the SAPN vaccine platform is versatile and can be modified to become self-adjuvanted thus expanding the options of vaccine design and development.
Materials and methods

Gene synthesis
A gene containing the SAPN core along with aTSR (Pf-3D7 strain residues 309-369) on the 5 0 end and six copies of the immunodominant B-cell repeat NANP on the 3 0 end was synthesized by GeneScript USA Inc. (Piscataway, NJ), resulting in the N-terminally His-tagged FMP014 cloned into a pPEP-T vector. A second gene containing the flagellin domains, D0 (residues 1-175) and D1 (residues 248-338), from Salmonella enterica serovar Typhimurium, connected by the short linker, QQKYKDGDKGDDK, was also synthesized by GeneScript USA Inc. The flagellin sequence was cloned into the vector replacing the (NANP) 6 repeat resulting in FMP014 D0D1 . The plasmids were separately transformed into the E. coli strain BL21 (DE3) (Life Technologies, Grand Island, NY) for protein expression.
The (E) Electron micrograph of nanoparticles formed in the FMP014 DOD1 formulation.
